Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told

This article was originally published in The Pink Sheet Daily

07 May 2015
News

Cathy Kelly Catherine.Kelly@informa.com

Executive Summary

Sandoz and other biosimilar stakeholders react at a public meeting to indications that CMS might be planning to put multiple biosimilars into a single Medicare billing code, meaning they would all be reimbursed at the same amount, when they reference the same innovator product.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Regions
North America

United States

Subjects
Medicare

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Medicare

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS078546

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS078546

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told

News

Executive Summary

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert